Rodman & Renshaw Initiates Coverage on BioAtla (NASDAQ:BCAB)

Stock analysts at Rodman & Renshaw started coverage on shares of BioAtla (NASDAQ:BCAB) in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The firm set a “buy” rating and a $4.00 price target on the stock.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of BioAtla in a research report on Friday, January 9th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $4.00.

BioAtla Stock Up 10.0%

BCAB stock opened at $0.34 on Tuesday. BioAtla has a 52 week low of $0.24 and a 52 week high of $1.43. The business has a 50-day simple moving average of $0.73 and a 200 day simple moving average of $0.61. The company has a market cap of $19.93 million, a PE ratio of -0.29 and a beta of 1.04.

BioAtla (NASDAQ:BCAB) last released its earnings results on Thursday, November 13th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.04. On average, analysts anticipate that BioAtla will post -1.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BCAB. Sheets Smith Investment Management acquired a new stake in shares of BioAtla during the 3rd quarter valued at $46,000. Woodline Partners LP bought a new position in BioAtla in the first quarter valued at about $26,000. Vanguard Group Inc. boosted its stake in shares of BioAtla by 9.1% during the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock valued at $1,339,000 after purchasing an additional 162,647 shares in the last quarter. Susquehanna International Group LLP grew its holdings in shares of BioAtla by 237.6% during the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after purchasing an additional 177,760 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in shares of BioAtla in the third quarter valued at approximately $235,000. 77.23% of the stock is currently owned by institutional investors.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.